StudyFinder



Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

A randomized, subject and investigator blinded, placebo controlled and multi-center platform study, to assess efficacy and safety of different investigational drugs in patients with moderate to severe hidradenitis suppurativa

Hidradenitis Suppurativa: Phase 2 Subject and Investigator Blinded, 7 and a half month study. Platform Study: Injectable and Oral drug, Males/Females 18-65 years old with Hidradenitis Suppurativa. Hidradenitis Suppurativa (HS) is a chronic recurrent and debilitating skin condition that typically presents with deep and painful lesions. The most common areas affected are the armpits, the groin, and the anus and genitals area. The purpose of the study is to find out if the study drugs (iscalimab and LYS006) are beneficial and safe in patients with HS.

For this study there are up to 11 visits over a period of 6 months. Subjects will take an oral medication twice a day for 16 weeks and will come to the study site for questionnaires, physical exams, EKGs, blood draws, and urine testing at multiple visits.

Up to $500.00

Yes
 

Joslyn Kirby
Samantha Gettle - at sgettle2@pennstatehealth.psu.edu or 717-531-5136
Dermatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03827798
STUDY00011808
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
HS diagnosis for at least 1 year
HS lesions in at least 2 affected areas

Exclusion Criteria:
Prior treatment to certain medications
Skin Conditions
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,